BioPharmSignal logoBioPharmSignal

Biotech News

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MaxCyte (MXCT)MaxCyteEarnings

First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million

Open original release

Related news

MXCTMaxCyte2026-03-24 20:05 EST

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

MXCTMaxCyte2026-02-23 21:05 EST

MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

SANASana Biotechnology2026-05-11 20:05 EST

Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates

RCKTRocket Pharmaceuticals2026-05-07 20:00 EST

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

SRPTSarepta Therapeutics2026-05-06 20:05 EST

Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments

CRSPCRISPR Therapeutics2026-05-04 20:30 EST

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

KRYSKrystal Biotech2026-05-04 11:00 EST

Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

RCKTRocket Pharmaceuticals2026-02-26 21:00 EST

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

SRPTSarepta Therapeutics2026-02-25 21:05 EST

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

KRYSKrystal Biotech2026-02-17 12:00 EST

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

View all latest news

MaxCyte

MaxCyte is a cell-engineering tools company that provides electroporation platforms used in cell therapy and gene therapy development. Its products support advanced-therapy manufacturing and research workflows.

Recent company news

MXCTMaxCyte2026-05-12 20:06 EST

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MXCTMaxCyte2026-04-29 20:05 EST

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

MXCTMaxCyte2026-03-31 20:05 EST

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MXCTMaxCyte2026-03-24 20:05 EST

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

MXCTMaxCyte2026-03-23 12:05 EST

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

Stock data

Close
1.02 USD
Market cap
131.76M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States